Company intelligence / Profile preview

RNAlfa Biotechnology

Hefei, Anhui Sheng, China

Ownership: Private
Development stage: Other

Overview

RNAlfa Biotechnology is a private Chinese biotech company founded in 2021 that develops prophylactic and therapeutic vaccines using an mRNA technology platform. The company has at least two clinical trials underway targeting infectious diseases and neoplasms. Its pipeline includes multiple mRNA-based vaccines, including a respiratory syncytial virus (RSV) candidate.

Therapeutic areas: NephrologyOncologyInfectious Diseases
Modalities: mRNA vaccinemRNAProphylactic vaccineTherapeutic vaccineRNA therapy
Industry: Biotech

Partnerships

None disclosed as of April 2025

Beyond the preview

Go deeper on RNAlfa Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNAlfa Biotechnology.

Explore the full profile